Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients
This real-world study showed BMD gains of 12% at the LS and 3.5% at the hip with 12 doses of romosozumab, and the relatively small diabetes subgroup limits the precision of this estimate.